Climb Bio to present budoprutug ITP trial data at ASH meeting
Climb Bio, a clinical-stage biotech company, will showcase budoprutug data for immune thrombocytopenia at the upcoming ASH meeting. The Phase 1b trial evaluated budoprutug, an anti-CD19 monoclonal antibody, in patients with a history of primary ITP. Three dose cohorts were studied, with safety, B-cell depletion, and platelet results presented at a poster session. Budoprutug targets CD19-expressing B cells. Climb Bio is developing other treatments for immune-mediated diseases, including CLYM116 for IgA nephropathy.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
